HTR4 and depressive symptom measurement: In this emulated target trial, the highly selective 5-HT4R agonist, prucalopride, was associated with a 13–21% lower risk of a first episode of depression within the following year, compared with matched cohorts of patients prescribed drugs with similar indication but without action at the 5-HT4R (linaclotide and lubiprostone).